Transcept Pharmaceuticals, Inc. to Present at the Natixis ...

Tag : Pharmaceuticals


An audio webcast of the presentation will be available at http://www.wsw.com/webcast/nblr2/transcept/ and on the Transcept website at http://www.transcept.com/ . The replay of the presentation will be available for 30 days.

About Transcept Pharmaceuticals

Transcept Pharmaceuticals is a specialty pharmaceutical companyfocused on the development and commercialization of proprietaryproducts that address important therapeutic needs in the fields ofpsychiatry and sleep medicine. The lead Transcept productcandidate, Intermezzo(R), is a sublingual low dose formulation ofzolpidem that has been developed for use as-needed for thetreatment of insomnia when a middle of the night awakening isfollowed by difficulty returning to sleep. Phase 3 clinical trialshave been completed for Intermezzo(R) and, on September 30, 2008,Transcept submitted a New Drug Application to the U.S. Food andDrug Administration. For further information, please visit thecompany's website at: http://www.transcept.com/ .

Safe Harbor

This press release contains forward-looking statements for purposesof the Private Securities Litigation Reform Act of 1995 (the"Act"). Transcept disclaims any intent or obligation toupdate these forward-looking statements, and claim the protectionof the Safe Harbor for forward-looking statements contained in theAct. Examples of such statements include, but are not limited to,the expected benefits of Transcept product candidates. Suchstatements are based on management's current expectations, butactual results may differ materially due to various risks anduncertainties, including, but not limited to, Transcept productcandidates may have unexpected adverse side effects or inadequatetherapeutic efficacy; positive results in clinical trials may notbe sufficient to obtain FDA approval; physician or patientreluctance to use Intermezzo(R), if approved; potential alternativetherapies; maintaining adequate patent or trade secret protectionwithout violating the intellectual property rights of others; andother difficulties or delays in, clinical development, obtainingregulatory approval, market acceptance and commercialization ofTranscept product candidates.

Transcept Pharmaceuticals, Inc.
Michael Gill
Director of Communications
(510) 215-3575
mgill@transcept.com

The Ruth Group
Investors / Media
Stephanie Carrington / Jason Rando
(646) 536-7017 / 7025
scarrington@theruthgroup.com
jrando@theruthgroup.com


Source: Transcept Pharmaceuticals, Inc.
CONTACT: Michael Gill, Director of Communications for Transcept
Pharmaceuticals, Inc., +1-510-215-3575, mgill@transcept.com ; or
Investors|Media, Stephanie Carrington, +1-646-536-7017,
scarrington@theruthgroup.com , or Jason Rando, +1-646-536-7025,
jrando@theruthgroup.com , both of The Ruth Group, for Transcept
Pharmaceuticals, Inc.

Web site: http://www.transcept.com/
http://www.wsw.com/webcast/nblr2/transcept

Printer Friendly Version Forward to a Friend